Research ExplorerPublicationsDisease risk and GVHD biomarkers can stratify patients for r...

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

Standard

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. / Aziz, Mina D; Shah, Jay; Kapoor, Urvi; Dimopoulos, Christina; Anand, Sarah; Augustine, Allan; Ayuk, Francis; Chaudhry, Mohammed; Chen, Yi-Bin; Choe, Hannah K; Etra, Aaron; Gergoudis, Stephanie; Hartwell, Matthew J; Hexner, Elizabeth O; Hogan, William J; Kitko, Carrie L; Kowalyk, Steven; Kröger, Nicolaus; Merli, Pietro; Morales, George; Nakamura, Ryotaro; Ordemann, Rainer; Pulsipher, Michael A; Qayed, Muna; Reshef, Ran; Rösler, Wolf; Schechter, Tal; Schreiner, Elisabeth; Srinagesh, Hrishikesh; Wölfl, Matthias; Wudhikarn, Kitsada; Yanik, Gregory; Young, Rachel; Özbek, Umut; Ferrara, James L M; Levine, John E.

In: LEUKEMIA, Vol. 34, No. 7, 07.2020, p. 1898-1906.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aziz, MD, Shah, J, Kapoor, U, Dimopoulos, C, Anand, S, Augustine, A, Ayuk, F, Chaudhry, M, Chen, Y-B, Choe, HK, Etra, A, Gergoudis, S, Hartwell, MJ, Hexner, EO, Hogan, WJ, Kitko, CL, Kowalyk, S, Kröger, N, Merli, P, Morales, G, Nakamura, R, Ordemann, R, Pulsipher, MA, Qayed, M, Reshef, R, Rösler, W, Schechter, T, Schreiner, E, Srinagesh, H, Wölfl, M, Wudhikarn, K, Yanik, G, Young, R, Özbek, U, Ferrara, JLM & Levine, JE 2020, 'Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant', LEUKEMIA, vol. 34, no. 7, pp. 1898-1906. https://doi.org/10.1038/s41375-020-0726-z

APA

Aziz, M. D., Shah, J., Kapoor, U., Dimopoulos, C., Anand, S., Augustine, A., Ayuk, F., Chaudhry, M., Chen, Y-B., Choe, H. K., Etra, A., Gergoudis, S., Hartwell, M. J., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kowalyk, S., Kröger, N., Merli, P., ... Levine, J. E. (2020). Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. LEUKEMIA, 34(7), 1898-1906. https://doi.org/10.1038/s41375-020-0726-z

Vancouver

Aziz MD, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A et al. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. LEUKEMIA. 2020 Jul;34(7):1898-1906. https://doi.org/10.1038/s41375-020-0726-z

Bibtex

@article{65e8c0444f4a4b5f98259969c8c6243a,
title = "Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant",
abstract = "The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers. In this study we tested whether the MAP could identify patients whose risk for relapse is higher than their risk for severe GVHD and NRM. The multicenter study population (n = 1604) was divided into two cohorts: historical (2006-2015, n = 702) and current (2015-2017, n = 902) with similar NRM, relapse, and survival. On day 28 post-HCT, patients who had not developed GVHD (75% of the population) and who possessed a low MAP were at much higher risk for relapse (24%) than severe GVHD and NRM (16 and 9%); this difference was even more pronounced in patients with a high disease risk index (relapse 33%, NRM 9%). Such patients are good candidates to test relapse prevention strategies that might enhance GVL.",
author = "Aziz, {Mina D} and Jay Shah and Urvi Kapoor and Christina Dimopoulos and Sarah Anand and Allan Augustine and Francis Ayuk and Mohammed Chaudhry and Yi-Bin Chen and Choe, {Hannah K} and Aaron Etra and Stephanie Gergoudis and Hartwell, {Matthew J} and Hexner, {Elizabeth O} and Hogan, {William J} and Kitko, {Carrie L} and Steven Kowalyk and Nicolaus Kr{\"o}ger and Pietro Merli and George Morales and Ryotaro Nakamura and Rainer Ordemann and Pulsipher, {Michael A} and Muna Qayed and Ran Reshef and Wolf R{\"o}sler and Tal Schechter and Elisabeth Schreiner and Hrishikesh Srinagesh and Matthias W{\"o}lfl and Kitsada Wudhikarn and Gregory Yanik and Rachel Young and Umut {\"O}zbek and Ferrara, {James L M} and Levine, {John E}",
year = "2020",
month = jul,
doi = "10.1038/s41375-020-0726-z",
language = "English",
volume = "34",
pages = "1898--1906",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

AU - Aziz, Mina D

AU - Shah, Jay

AU - Kapoor, Urvi

AU - Dimopoulos, Christina

AU - Anand, Sarah

AU - Augustine, Allan

AU - Ayuk, Francis

AU - Chaudhry, Mohammed

AU - Chen, Yi-Bin

AU - Choe, Hannah K

AU - Etra, Aaron

AU - Gergoudis, Stephanie

AU - Hartwell, Matthew J

AU - Hexner, Elizabeth O

AU - Hogan, William J

AU - Kitko, Carrie L

AU - Kowalyk, Steven

AU - Kröger, Nicolaus

AU - Merli, Pietro

AU - Morales, George

AU - Nakamura, Ryotaro

AU - Ordemann, Rainer

AU - Pulsipher, Michael A

AU - Qayed, Muna

AU - Reshef, Ran

AU - Rösler, Wolf

AU - Schechter, Tal

AU - Schreiner, Elisabeth

AU - Srinagesh, Hrishikesh

AU - Wölfl, Matthias

AU - Wudhikarn, Kitsada

AU - Yanik, Gregory

AU - Young, Rachel

AU - Özbek, Umut

AU - Ferrara, James L M

AU - Levine, John E

PY - 2020/7

Y1 - 2020/7

N2 - The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers. In this study we tested whether the MAP could identify patients whose risk for relapse is higher than their risk for severe GVHD and NRM. The multicenter study population (n = 1604) was divided into two cohorts: historical (2006-2015, n = 702) and current (2015-2017, n = 902) with similar NRM, relapse, and survival. On day 28 post-HCT, patients who had not developed GVHD (75% of the population) and who possessed a low MAP were at much higher risk for relapse (24%) than severe GVHD and NRM (16 and 9%); this difference was even more pronounced in patients with a high disease risk index (relapse 33%, NRM 9%). Such patients are good candidates to test relapse prevention strategies that might enhance GVL.

AB - The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers. In this study we tested whether the MAP could identify patients whose risk for relapse is higher than their risk for severe GVHD and NRM. The multicenter study population (n = 1604) was divided into two cohorts: historical (2006-2015, n = 702) and current (2015-2017, n = 902) with similar NRM, relapse, and survival. On day 28 post-HCT, patients who had not developed GVHD (75% of the population) and who possessed a low MAP were at much higher risk for relapse (24%) than severe GVHD and NRM (16 and 9%); this difference was even more pronounced in patients with a high disease risk index (relapse 33%, NRM 9%). Such patients are good candidates to test relapse prevention strategies that might enhance GVL.

U2 - 10.1038/s41375-020-0726-z

DO - 10.1038/s41375-020-0726-z

M3 - SCORING: Journal article

C2 - 32020045

VL - 34

SP - 1898

EP - 1906

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 7

ER -